Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

This study tests whether a drug called sunvozertinib, combined with standard chemotherapy, can help people with non-small cell lung cancer (NSCLC) whose tumors have a specific genetic mutation (EGFR) and have stopped responding to previous targeted therapy. **You may be eligible if...** - You are 18–80 years old - You have non-squamous NSCLC with an EGFR mutation (exon 19 deletion, L858R, or T790M) - Your cancer has become resistant to or you cannot tolerate standard EGFR-targeted therapy - You have not had chemotherapy for advanced or metastatic disease - You have measurable tumors on imaging - Brain metastases are allowed if stable or previously treated **You may NOT be eligible if...** - You have spinal cord compression or cancer spread to the membranes around the brain - You have had another cancer within the past 2 years - You have had a stroke or brain bleed within the last 6 months - You have poorly controlled infections including hepatitis B, C, or HIV Talk to your doctor to see if this trial is right for you.